CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

2017/11/20 by Terry J Fry, Terry J. Fry, Nirali N. Shah +35 · 3 citations
Engineering · Immunology and Microbiology · Medicine · #CAR-T cell therapy research #Immune Cell Function and Interaction #Silicon Carbide Semiconductor Technologies

paper · doi:10.1038/nm.4441

crossref issued 2017/11/20 · crossref published 2017/11/20 · crossref published-online 2017/11/20 · openalex publication_date 2017/11/20 · crossref created 2017/11/20 · crossref published-print 2018/01/01 · crossref deposited 2025/02/11 · openalex created_date 2025/10/10 · crossref indexed 2026/07/31 · openalex updated_date 2026/08/01

Citations

• Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
• Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

Cited by

• Women in immunology: 2020 and beyond
• Mechanisms of resistance to CAR T cell therapy
• Nirali N. Shah [wikipedia]